Reference Links:

Lord BI, Woolford LB, Wood LM, Czaplewski LG, McCourt M, Hunter MG, Edwards RM.  Mobilisation of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha.  Blood 85(12) 3412-3415, 1995.

Wark G., Heyworth CM., Spooncer E., Czaplewski L., Francis JM., Dexter TM., Whetton AD.  Abl protein kinase abrogates the response of multipotent haematopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha.  Oncogene 16(10), 1319-1324, 1998.

Marshall E., Lord BI., Howell AH., Powles R., Hunter MG., Edwards M, Wood LM., Czaplewski LG., Puttick R., Warington S., Boyce M., Testa N., Dexter TM., Lord BI., Millar A. Clinical effects of human MIP�1alpha (LD78) administration to humans: A phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant BB�10010. European Journal of Cancer 34(7), 1023-1029, 1998.

Clemons MJ., Marshall E., Durig J., Watanabe K., Howell A., Miles D., Earl H., Kiernan J., Griffiths A., Towlson K., DeTakats P., Testa NG., Dougal M., Hunter MG., Wood LM., Czaplewski LG., Millar A., Dexter TM., Lord BI. A randomised phase-II study of BB-10010 (Macrophage inflammatory protein-1 alpha with advanced breats cancer receiving 5-FU, adriamycin and cyclophosphamide (FAC) chemotherapy.  Blood 92, 1532-1540, 1998.